Le Plan Stratégique National de Lutte contre le Paludisme au Sénégal 2021–2025 a pour objectif de réduire l’incidence et la mortalité liées au paludisme d’au moins 75 % par rapport à 2019 et d’interrompre la transmission locale dans au moins 80 % des districts éligibles. Il repos...e sur une approche multisectorielle combinant prévention (moustiquaires, pulvérisation, chimioprévention), diagnostic, traitement, surveillance, gestion des stocks et communication pour le changement de comportement. Le plan vise aussi à renforcer la gouvernance, l’équité, la recherche et la mobilisation des ressources, en s’appuyant sur les partenariats locaux, privés et internationaux pour atteindre l’objectif d’un Sénégal sans paludisme à l’horizon 2030.
more
La Stratégie Nationale de Plaidoyer et de Mobilisation des Ressources en faveur de la Lutte contre le Paludisme 2024–2028 en République Démocratique du Congo vise à renforcer l’engagement politique, mobiliser des financements domestiques et internationaux et impliquer tous les secteurs (publ...ic, privé, société civile) pour réduire la mortalité liée au paludisme de 70 % et l’incidence de 50 % d’ici 2028.
Le document propose des actions concrètes : plaidoyer auprès des décideurs pour des budgets accrus, exonération des intrants antipaludiques, introduction du vaccin R21/Matrix-M, création de partenariats public-privé, implication des leaders communautaires et campagnes de sensibilisation via les médias. Il s’aligne sur la stratégie mondiale de l’OMS et promeut une approche multisectorielle, coordonnée par le Programme National de Lutte contre le Paludisme avec l’appui de partenaires comme l’USAID et Breakthrough ACTION.
more
Le Plan d'action régional pour la vaccination dans les Amériques (RIAP) constitue une étape fondamentale pour consolider les progrès accomplis et offre une vision concrète pour relever les défis actuels et futurs en vue d'atteindre les objectifs fixés pour l'année 2030. Ce plan est essentiel... pour renforcer les systèmes de santé, améliorer l'accès à la vaccination et optimiser la coordination entre les parties prenantes, en veillant à ce que tous les secteurs de la population aient la possibilité de bénéficier de programmes de vaccination résilients, efficaces et équitables tout au long du parcours de vie. Conçu dans le cadre stratégique de la politique pour la Revitalisation de la vaccination en tant que bien de santé publique pour une santé universelle et aligné sur le Programme pour la vaccination à l’horizon 2030, le plan d’action synthétise les priorités déterminées par les pays et les territoires, en utilisant des indicateurs qui ciblent six axes stratégiques d’intervention : la gouvernance, la surveillance, l'intégration, la communication, les ressources humaines et la prise de décision fondée sur des données probantes. Cette approche globale et inclusive réaffirme la volonté de parvenir à la couverture sanitaire universelle et d'atteindre les objectifs de développement durable. À l'avenir, il sera essentiel de maintenir un engagement fort à tous les niveaux en adaptant les stratégies aux changements que connaîtront les pays et les territoires, afin de faire progresser efficacement leurs efforts de vaccination par la mise en œuvre de meilleures pratiques et d’approches novatrices. Toutes les parties prenantes sont encouragées à participer à cet effort collectif pour que la vaccination soit considérée comme un bien public et que la population soit protégée contre les maladies évitables par la vaccination.
more
Malaria No More is a non-profit organisation dedicated to eradicating malaria, a preventable and treatable disease, in our lifetime. Through innovative partnerships, advocacy and data-driven solutions, Malaria No More works globally to ensure access to prevention tools, diagnostics and treatment, pa...rticularly in vulnerable regions. Malaria No More focuses on high-impact campaigns, technological innovation and policy engagement, collaborating with governments, health organisations and private sector partners to accelerate progress towards malaria eradication and save lives.
more
The RBM Partnership to End Malaria is a global coalition comprising over 500 partners, including governments, international organisations, the private sector and civil society, who are all dedicated to ending malaria worldwide. Through coordinated advocacy, resource mobilisation and technical suppor...t, the Partnership strengthens national malaria control programmes and accelerates progress towards malaria elimination.
more
Asthma has a significant impact on people of all ages, particularly children. A lack of universally accepted case definition and confirmatory tests and a poor understanding of major risks interfere with a global response. We aimed to provide global estimates of asthma prevalence and cases in 2019 ac...ross four main epidemiological case definitions – current wheezing, ever wheezing, current asthma, and ever asthma. We further investigated major associated factors to determine regional and national distributions of prevalence and cases for current wheezing and ever asthma.
more
The Noncommunicable Diseases (NCD) Data Portal offers comprehensive data on NCDs such as cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases. It provides country-specific information on NCD mortality rates, risk factors, and national responses, facilitating analysis and compa...rison across regions. The portal also includes resources like publications and tools to support global efforts in NCD prevention and control.
more
Severe and difficult asthma in a low- and middle-income country (LMIC) can relate to lack of availability of basic medications; potentially reversible factors such as poor adherence or comorbidities such as obesity inhibiting a good response to treatment; and (rarely) true severe, therapy-resistant ...asthma. However, definitions of severity should encompass not merely doses of prescribed medication, but also underlying risk. The nature of asthmatic airway disease shows geographical variation, and LMIC asthma should not be assumed to be phenotypically the same as that in high-income countries (HICs). The first assessment step is to ensure another diagnosis is not being missed. Largely, political action is needed if children with asthma are to get access to basic medications. If a child is apparently not responding to low dose, simple medications, the next step is not to increase the dose but perform a detailed assessment of what factors (for example co-morbidities such as obesity, or social factors like poor adherence) are inhibiting a treatment response; in most cases, an underlying reason can be found. An assessment of risk of future severe asthma attacks, side-effects of medication and impaired lung development is also important. True severe, therapy-resistant asthma is rare and there are multiple underlying molecular pathologies. In HICs, steroid-resistant eosinophilia would be treated with omalizumab or mepolizumab, but the cost of these is prohibitive in LMICs, the biomarkers of successful therapy are likely only relevant to HICs. In LMICs, a raised blood eosinophil count may be due to parasites, so treating asthma based on the blood eosinophil count may not be appropriate in these settings.
more
Chronic obstructive pulmonary disease (COPD) is a term used to describe chronic lung diseases including emphysema and chronic bronchitis. COPD is characterized by breathlessness. Some people with COPD also experience tiredness and chronic cough with or without mucus.
The Noncommunicable Diseases (NCD) Data Portal offers comprehensive data on NCDs such as cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases. It provides country-specific information on NCD mortality rates, risk factors, and national responses, facilitating analysis and compa...rison across regions. The portal also includes resources like publications and tools to support global efforts in NCD prevention and control.
more
The Noncommunicable Diseases (NCD) Data Portal offers comprehensive data on NCDs such as cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases. It provides country-specific information on NCD mortality rates, risk factors, and national responses, facilitating analysis and compa...rison across regions. The portal also includes resources like publications and tools to support global efforts in NCD prevention and control.
more
The Noncommunicable Diseases (NCD) Data Portal offers comprehensive data on NCDs such as cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases. It provides country-specific information on NCD mortality rates, risk factors, and national responses, facilitating analysis and compa...rison across regions. The portal also includes resources like publications and tools to support global efforts in NCD prevention and control.
more
The Noncommunicable Diseases (NCD) Data Portal offers comprehensive data on NCDs such as cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases. It provides country-specific information on NCD mortality rates, risk factors, and national responses, facilitating analysis and compa...rison across regions. The portal also includes resources like publications and tools to support global efforts in NCD prevention and control.
more
The pharmacological management of asthma has changed considerably in recent decades, as it has come to be understood that it is a complex, heterogeneous disease with different phenotypes and endotypes. It is now clear that the goal of asthma treatment should be to achieve and maintain control of the... disease, as well as to minimize the risks (of exacerbations, disease instability, accelerated loss of lung function, and adverse treatment effects). That requires an approach that is personalized in terms of the pharmacological treatment, patient education, written action plan, training in correct inhaler use, and review of the inhaler technique at each office visit. A panel of 22 pulmonologists was invited to perform a critical review of recent evidence of pharmacological treatment of asthma and to prepare this set of recommendations, a treatment guide tailored to use in Brazil. The topics or questions related to the most significant changes in concepts, and consequently in the management of asthma in clinical practice, were chosen by a panel of experts. To formulate these recommendations, we asked each expert to perform a critical review of a topic or to respond to a question, on the basis of evidence in the literature. In a second phase, three experts discussed and structured all texts submitted by the others. That was followed by a third phase, in which all of the experts reviewed and discussed each recommendation. These recommendations, which are intended for physicians involved in the treatment of asthma, apply to asthma patients of all ages.
more
The pharmacological management of asthma has changed considerably in recent decades, as it has come to be understood that it is a complex, heterogeneous disease with different phenotypes and endotypes. It is now clear that the goal of asthma treatment should be to achieve and maintain control of the... disease, as well as to minimize the risks (of exacerbations, disease instability, accelerated loss of lung function, and adverse treatment effects). That requires an approach that is personalized in terms of the pharmacological treatment, patient education, written action plan, training in correct inhaler use, and review of the inhaler technique at each office visit. A panel of 22 pulmonologists was invited to perform a critical review of recent evidence of pharmacological treatment of asthma and to prepare this set of recommendations, a treatment guide tailored to use in Brazil. The topics or questions related to the most significant changes in concepts, and consequently in the management of asthma in clinical practice, were chosen by a panel of experts. To formulate these recommendations, we asked each expert to perform a critical review of a topic or to respond to a question, on the basis of evidence in the literature. In a second phase, three experts discussed and structured all texts submitted by the others. That was followed by a third phase, in which all of the experts reviewed and discussed each recommendation. These recommendations, which are intended for physicians involved in the treatment of asthma, apply to asthma patients of all ages.
more